Sign up to save your podcasts
Or
Share Christopher Brightling on tezepelumab in patients with moderate-to-severe uncontrolled asthma
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
Christopher Brightling on tezepelumab in patients with moderate-to-severe uncontrolled asthma
Christopher Brightling discusses the effect of blocking thymic stromal lymphopoietin (TSLP) with tezepelumab in patients with moderate-to-severe uncontrolled asthma.
Read the full article:
https://www.thelancet.com/journals/lanres/article/PIIS2213-2600(21)00226-5/fulltext
Continue this conversation on social!
Follow us today at...
https://thelancet.bsky.social/
https://instagram.com/thelancetgroup
https://facebook.com/thelancetmedicaljournal
https://linkedIn.com/company/the-lancet
https://youtube.com/thelancettv
View all episodes
By The Lancet Group
5
11 ratings
Christopher Brightling discusses the effect of blocking thymic stromal lymphopoietin (TSLP) with tezepelumab in patients with moderate-to-severe uncontrolled asthma.
Read the full article:
https://www.thelancet.com/journals/lanres/article/PIIS2213-2600(21)00226-5/fulltext
Continue this conversation on social!
Follow us today at...
https://thelancet.bsky.social/
https://instagram.com/thelancetgroup
https://facebook.com/thelancetmedicaljournal
https://linkedIn.com/company/the-lancet
https://youtube.com/thelancettv
More shows like The Lancet Respiratory Medicine in conversation with
View all
JAMA Editors' Summary
139 Listeners
Annals of Internal Medicine Podcast
135 Listeners
NEJM This Week
325 Listeners
JAMA Clinical Reviews
498 Listeners
CHEST Journal Podcasts
64 Listeners
Diabetes Core Update
101 Listeners
Out of the Blue: An AJRCCM Podcast
37 Listeners
ERS Publications Podcasts
6 Listeners
Health Report
130 Listeners
The Daily
112,593 Listeners
BMJ Best Practice Podcast
20 Listeners
Core IM | Internal Medicine Podcast
1,148 Listeners
The Lancet Voice
21 Listeners
The Lancet Child & Adolescent Health in conversation with
0 Listeners
The Lancet Digital Health in conversation with
0 Listeners
The Lancet Global Health in conversation with
2 Listeners
The Lancet Oncology in conversation with
1 Listeners
The Lancet Psychiatry in conversation with
0 Listeners
The Lancet in conversation with
0 Listeners
The Lancet Haematology in conversation with
0 Listeners
The Lancet Gastroenterology & Hepatology in conversation with
0 Listeners
The Lancet Diabetes & Endocrinology in conversation with
1 Listeners
The Lancet Infectious Diseases in conversation with
0 Listeners
The Lancet Public Health in conversation with
1 Listeners
The Lancet Microbe in conversation with
0 Listeners
eBioMedicine in conversation with
0 Listeners
In conversation with...
0 Listeners
PulmPEEPs
59 Listeners
The Lancet Rheumatology in conversation with
0 Listeners
The Lancet Regional Health in conversation with
0 Listeners
The Lancet Primary Care in conversation with
0 Listeners
The Lancet Regional Health Americas in conversation with
0 Listeners